Inhibrx Biosciences, Inc. (NASDAQ: INBX) CEO Boosts Stake Amidst Positive Clinical Trial Results and Strong Clinical Data

• Inhibrx Biosciences, Inc. (NASDAQ: INBX) CEO demonstrated strong confidence with a significant insider purchase of shares.
• The company announced positive Phase 2 HexAgon study results for its cancer drug candidate, INBRX-106, showing superior efficacy when combined with Keytruda.
• Despite a stock dip following the positive news, the CEO's purchase near the day's low suggests a belief in the company's long-term value and future growth potential.

Inhibrx Biosciences, Inc. (NASDAQ: INBX) is a clinical-stage biotechnology company that develops new treatments for various diseases. The company is currently focused on its cancer drug candidate, INBRX-106. This drug is being tested in combination with Keytruda, a well-known cancer therapy from competitor Merck & Co Inc., for treating head and neck cancer.

On September 8, 2026, Chief Executive Officer Lappe Mark purchased 5,895 shares of Inhibrx Biosciences common stock. The shares were bought at a price of $99.29 each. This significant insider purchase increased the CEO's total ownership in the company to 711,443 shares, signaling strong confidence from company leadership.

This purchase coincided with major company news. Inhibrx Biosciences announced positive clinical trial results from its Phase 2 HexAgon study. The study showed its drug INBRX-106, when combined with Keytruda, achieved a 48.3% confirmed objective response rate (cORR). This rate, which measures tumor shrinkage, was much higher than the 26.5% cORR for patients taking Keytruda alone.

The combination therapy also demonstrated an interim median progression-free survival (PFS) of 9.6 months. PFS measures the length of time a patient lives with a disease without it getting worse. As highlighted by Reuters, the drug successfully reduced tumors in the mid-stage study for a specific type of head and neck cancer.

Despite this positive clinical data, Inhibrx Biosciences stock experienced a daily decrease of 5.64%, closing at $114.34. The CEO's purchase at $99.29 occurred near the day's trading low of $94.00. This action suggests a belief in the company's value beyond the market's immediate reaction to the news, highlighting strong investment confidence.